Require insurance coverage of continuous glucose monitoring supplies
The enactment of HB 758 will amend existing provisions within the Montana Code Annotated, specifically targeting insurance policies to include comprehensive coverage for diabetes management technologies. It will affect all disability policies issued or renewed after January 1, 2024. The bill proposes that continuous glucose monitoring coverage cannot have special deductibles or copayment provisions that are not also applicable to other medical services, which could lead to a more equitable healthcare financing structure for affected individuals.
House Bill 758, introduced in the Montana Legislature, mandates insurance coverage for continuous glucose monitors and associated supplies for individuals diagnosed with Type I or Type II diabetes. This legislation aims to ensure that these medical devices, which are essential for managing blood sugar levels, are accessible and included under insurance plans without imposing restrictive conditions related to the stages of the disease. By establishing this requirement, the bill seeks to enhance the quality of healthcare for those living with diabetes, thus potentially improving their overall health outcomes and daily living standards.
The reception of HB 758 appears largely positive among healthcare advocates and patient groups who argue that greater access to diabetes management tools is essential. However, there are concerns voiced by some insurance stakeholders regarding increased costs associated with the bill. A sentiment of supporting healthcare access is prevalent, with proponents emphasizing the necessity of monitoring devices in preventing serious health complications for diabetic patients.
Despite favorable views, there are discussions regarding the potential financial implications for insurance providers in adapting to these new coverage requirements. Critics worry that mandating coverage for continuous glucose monitors without limitations could lead to increased insurance premiums across the board. The pushback suggests a need for a dialogue on balancing patient access to essential medical devices with the financial sustainability of insurance plans.